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The small GTPase Rab5 controls the fusogenic 
properties of early endosomes through activation of 
effector proteins. Expression of a GTPase-defective 
mutant, Rab5(Q79L), is known to cause formation of 
enlarged early endosomes. To identify proteins inte-
racting with this GTP-bound form of active Rab5 [1], 
we used a two-hybrid system to screen a human fetal 
cDNA library with a human Rab5A protein bearing a 
mutation of Q79L as bait. The positive clone cDNAs 
were reconfirmed to be interaction-positive by using 
an independent yeast clone containing the bait. Then, 
more than 3 positive preys were identified, and sub-
sequent sequence analysis revealed one of the preys to 
be RUFY3: RUN and FYVE domain containing 3. We 
performed double immunefluorescent staining for 
human RUFY3 and human Rab5A(Q79L) in 3Y1 cells. 
Analysis with confocal microscopy clearly showed 
that the Rab5(Q79L) and the RUFY3 colocalized in 
large vesicle structures in 3Y1 cells (data not shown). 
This indicated an interaction between RUFY3 and 
Rab5(Q79L), which may be altered by the nucleo-
tide-bound state of Rab5. We checked this possibility 
using other Rab5 mutant. The Rab5(S34N) mutant 
preferentially binds GDP, whereas the Rab5(Q79L) 
mutant is unable to hydrolyze bound GTP. As shown 
in Figure 1, the superimposed image by confocal mi-
croscopy again confirmed the cytoplasmic vesicular 
localization of RUFY3 with constitutively active 
Rab5(Q79L) well colocalized in almost all vesicles, 
whereas not with dominant negative Rab5(S34N). 
These data clearly indicated that RUFY3 was localized 
in enlarged vesicles with the active GTP-bound form 
of Rab5, where Rab5(Q79L) sequester RUFY3. How-
ever, there is an another possibility for the phenome-
non seen in Figure 1, that Rab5(Q79L) mutant inhi-
bited endosome traffic and resulted in RUFY3 accu-
mulation in Rab5(Q79L) compartment. 
We next determined whether Rab5 was asso-
ciated with RUFY3 by glutathione S-transferase (GST) 
pull-down assays. We found that carboxyl terminal 
domain of RUFY3 was associated with Rab5 in v-SRC 
transformed SRD cells (Fig. 2A), but not in normal 
3Y1 cells and 293T cells (data not shown). The RUN 
domain of RUFY3 as well as control GST protein was 
not able to bind Rab5 (Fig. 2A, upper panel). In this 
assay, we found that Rap2 was weakly bound to the 
RUN domain of RUFY3 (Figure 2A, middle panel), 
which was consistent with the previous reports [2]. 
All the other small GTPases including Ran (Figure 2A, 
lower panel) [3], Rab2, Rab7, Rho, Ras did not bind to 
RUFY3 (data not shown). These data suggested that 
RUFY3 could bind to Rab5 and Rap2. As a comple-
mentary approach, we also used a pull-down assay 
with immobilized GST-Rab5 fusion proteins [4] pre-
loaded with GTP (GST-Rab5(Q79L)) but not with 
GDP (GST-Rab5(S34N)) could bind to RUFY3 (Figure 
2B). Finally, we examined the biochemical in vivo 
endogenous interactions between Rab5 and RUFY3 
(Figure 2C). U937 (monocyte-derived resident ma-
crophage) cells were subjected to immunoprecipita-
tion using either anti-Rab5 or anti-RUFY3 antibodies. 
As shown in Figure 2C, Rab5, but not control, was 
coprecipitated with RUFY3. Reciprocally, RUFY3 was 
coprecipitated with Rab5, but not with the mock an-
tibody.  
The two-hybrid assay also revealed that the 
carboxyl terminal region of RUFY3 was necessary for 




the first 390 residues of RUFY3 did not interact with 
Rab5(Q79L) (data not shown). The carboxyl terminal 
region of the RUFY3 is predicted to be mainly al-
pha-helical and contains coiled-coil domains, as de-
termined according to the Lupas algorithm. The 
RUFY gene family (RUFY1, RUFY2), which is most 
similar structure to RUFY3, contains an amino ter-
minal RUN domain and a carboxyl terminal FYVE 
domain [5] with two coiled-coil domains in-between 
[6]. The RUFY proteins are localized predominantly to 
endosomes as evidenced by their colocalization with 
early endosome antigen marker (EEA1) [6]. However, 
both RUFY1 and RUFY2 have not been shown to as-
sociate with active Rab5. The endosomal localization 
of EEA1 was also determined by its ability to bind 
Rab5 [7]. To our knowledge, the region has not been 
identified as a general binding motif for active Rab5.  
The GTP-bound active form of Rab5 localized on 
the cytoplasmic face of early endosomes, and pro-
motes membrane trafficking through interaction with 
specific effector molecules such as EEA1 [8].The mode 
of action of Rab5 in phagosomal maturation remain 
obscure. However, it has been reported that oxidized 
low density lipoprotein interferes with normal pha-
gosomal maturation, possibly via blocking membrane 




Figure 1. Colocalization of RUFY3 and active Rab5(Q79L). The 3Y1 cells were transiently transfected with either 
GFP-tagged-Rab5(S34N) and pcDNA3.1-RUFY3 (left panels), or GFP-tagged-Rab5(Q79L) and pcDNA3.1-RUFY3 (right 
panels). The cells were then fixed and incubated with anti- RUFY3 antibodies followed by staining with rhoda-
mine-conjugated secondary antibodies. Images were obtained using a confocal microscope. The merged figures show images 
of green (GFP-labeled proteins) and red rhodamine labeling obtained for the same section, with yellow color resulting from 
the overlay of green and red. Polyclonal anti-RUFY3 antibody was prepared in rabbits immunized with the NH2-terminal 
region of human RUFY3 as GST fusion proteins. Antibodies (Rab5:sc46692; Rab5A:sc309) were purchased from Santa Cruz 






Figure 2. (A) Interaction between the full-length RUFY3 and various small GTPase proteins were analyzed in the GST pull 
down assay with GST only, GST fusion of RUFY3 C terminal region (370-469) or of RUFY3 RUN domain (93-232). These 
GST fusion proteins were immobilized on glutathione-agarose beads and mixed with SRD cell lysates. Bound proteins were 
separated by SDS-PAGE and immunoblotted with the GTPase protein antibodies indicated in the figure. (B) GST-Rab5 
proteins in various nucleotide-bound state mutants were allowed to bind RUFY3. RUFY3 was expressed in 293T cells and 
subjected to GST pull-down assay with GST-Rab5 fusion protein conjugated resin. Bound proteins were separated by 
SDS-PAGE and immunoblotted with anti-RUFY3 antibody. (C) Coimmunoprecipitaion of Rab5 with RUFY3. U937 cell 
lysates containing co-expressed RUFY3 were immunoprecipitated by anti-Rab5 (upper panel) or anti-RUFY3 (lower panel) 
antibodies, followed by SDS-PAGE and immunoblot analysis with anti-RUFY3 or anti-Rab5 antibodies, respectively. 
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